Lilly Completes Deal with BioMS, Signs Agreement with Gastrotech
Eli Lilly and Company (Indianapolis, IN) has completed its licensing and development agreement with BioMS Medical Corp. (Edmonton, Alberta, Canada).
Eli Lilly and Company (Indianapolis, IN) has completed its licensing and development agreement with BioMS Medical Corp. (Edmonton, Alberta, Canada). As part of the agreement, BioMS received an upfront cash payment of $87 million. In December 2007, BioMS Medical entered into a global licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead drug, MBP8298, for the treatment of multiple sclerosis (MS).
Lilly has also signed an agreement with Gastrotech Pharma (Copenhagen, Denmark) to in-license a Lilly compound (formerly known as LY307161, now named GTP-010), an analogue of the naturally occurring intestinal hormone GLP-1. The deal follows recent clinical data from a joint Gastrotech and Lilly proof-of-concept study to assess pain reduction associated with irritable bowel syndrome (IBS). Gastrotech now plans to develop GTP-010 to treat IBS. Financial terms of the deal were not disclosed.
BioMS Medical release (PDF)
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
